Cardium Therapeutics Inc. reported consolidated financial results for the third quarter and nine months ended September 30, 2013. For the quarter, the company reported total product sales of $472,000, compared to $5,600 for the same period in 2012. Net loss was $1,769,005 compared to $1,894,920 last year. Net loss applicable to common stockholders was $1,941,866 or $0.28 per basic and diluted share compared to $1,894,920 or $0.32 per basic and diluted share last year. Loss from operations was $1,769,005 compared to $1,896,124 last year.

For the nine months, the company reported loss from operations of $6,147,687 compared to loss from operations of $6,432,331 for the same period a year ago. Net loss was $6,148,908 compared to $6,364,403 last year. Net loss applicable to common stockholders was $6,554,780 or $0.99 per basic and diluted share compared to $6,364,403 or $1.10 per basic and diluted share last year. Product sales for the nine months ended September 30, 2013 were $1.7 million, compared to $39,000 for the nine months ended September 30, 2012. The increase in product sales was comprised of sales from the company's To Go Brands health sciences business, which Cardium acquired in late September 2012.